A comprehensive review of the safety profile of bone morphogenetic protein in spine surgery.

摘要: WE REVIEW OUR current understanding of the development and potential clinical applications bone morphogenetic protein (BMP) in spine surgery. We also review evidence for adverse events associated with use BMP suggest reasons these means complication avoidance. Bone 2 (rhBMP-2) is approved by Food Drug Administration anterior lumbar interbody fusion; rhBMP-7, on other hand, long defects has received a humanitarian device exemption revision posterolateral operations recalcitrant unions. Nevertheless, "off-label" various spinal procedures been reported increasing frequency. Specific guidelines rhBMP-2 rhBMP-7 are lacking because limited availability randomized controlled trials its diverse many applications. Mechanisms delivery, carrier type, graft position, surgical location, variations concentration may differ from one surgery to next. Adverse linked either or include ectopic formation, resorption remodeling at site, hematoma, neck swelling, painful seroma. Other theoretical concerns carcinogenicity teratogenic effects. In this review, we provide reader historical perspective BMP, past research support procedures, critical analysis complications thus far.